Hepatocellular Cancer

P=N/A, N=300, Completed, Sun Yat-sen University

P1, N=171, Recruiting, SEED Therapeutics, Inc. | Not yet recruiting --> Recruiting

miR-876-3p could reverse the functions of HOXC-AS1 for HCC cells by targeting NR3C1. Upregulation of HOXC-AS1 promotes HCC progression through the miR-876-3p/NR3C1 axis.

These findings demonstrate that CB-839 exhibits significant antifibrotic effects in a rat model of liver fibrosis, primarily by modulating glutamine metabolism and key fibrotic biomarkers. CB-839 has the potential to be a promising therapeutic approach for liver fibrosis.

It effectively inhibited tumor growth in HCCLM3 xenograft tumor models while demonstrating a favorable safety profile. Taken together, this study introduces a promising 3-(Phenylsulfonamido) benzamide derivative as a novel approach to targeting PLAGL2 transcriptional activity, laying a foundation for future investigations in anti-tumor therapy.

P2, N=50, Not yet recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Dec 2028 --> Jan 2030 | Trial primary completion date: May 2028 --> Jan 2030

P=N/A, N=200, Not yet recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

P=N/A, N=20, Recruiting, Fondazione IRCCS Policlinico San Matteo di Pavia

These consequences boosted by reduction in several hepatic inflammation markers and distressed the structural restoration of the liver's histological images. In conclusion, the combination of CEE and Silymarin® exert a hepatoprotective complement manner as attributed to the synergistic effect of CEE and Silymarin®.

Our study demonstrates the first successful expansion of adaptive NK cells with robust functional responses from donors with chronic viral infection. This approach creates opportunities for NK cell-based therapies alone or in combination with monoclonal antibodies contributing to HBV functional cure strategies and the treatment of HBV-driven cancers.

1.This study investigated the synergistic effect of L-arginine (iNOS substrate) combined with 5-fluorouracil (5-FU, iNOS inducer) on epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma (HCC).2.In vitro, the combination significantly inhibited HCC cell proliferation, invasion, migration, and upregulated iNOS. It also decreased mesenchymal markers (N-cadherin, vimentin, Snail, Slug) and increased epithelial E-cadherin.3.In vivo, using DEN-induced HCC rats, the combination group showed extensive tumor necrosis, reduced mitoses, enhanced iNOS, reduced mesenchymal markers, elevated E-cadherin, fewer pseudopodia, and increased cytoplasmic vacuolation compared to the model group.4.Thus, L-arginine + 5-FU synergistically inhibits HCC metastasis by suppressing EMT via iNOS upregulation.